Sarepta Therapeutics Stock
Sarepta Therapeutics Stock
Sarepta Therapeutics gained 1.770% today.
The community is currently still undecided about Sarepta Therapeutics with 1 Buy predictions and 0 Sell predictions.
With a target price of 130 € there is a slightly positive potential of 8.02% for Sarepta Therapeutics compared to the current price of 120.35 €.
So far the community has only identified positive things for Sarepta Therapeutics stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Sarepta Therapeutics in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Sarepta Therapeutics vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Sarepta Therapeutics | 1.770% | 10.871% | 0.083% | 7.986% | 36.019% | 108.218% | 10.413% |
Exact Sciences | 1.920% | -3.932% | -14.136% | -5.469% | -19.787% | -50.963% | -37.134% |
Incyte Corp. | 0.290% | -2.680% | -8.542% | -28.502% | -14.892% | -31.014% | -27.098% |
Regeneron Pharmaceuticals Inc. | -0.440% | -1.902% | -7.333% | 13.352% | 3.473% | 105.197% | 169.102% |
Comments
News
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Sarepta Therapeutics (NASDAQ: SRPT) could have a serious new competitor on the horizon. According to some fresh clinical data from Regenxbio (NASDAQ: RGNX), another biotech, the company is making
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
On Feb. 20, Wedbush financial analyst Andreas Argyrides restated his price target for Sarepta Therapeutics (NASDAQ: SRPT) stock, claiming that its shares would reach $224, rising 73% in the process
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
Sarepta Therapeutics (NASDAQ: SRPT)Q4 2023 Earnings CallFeb 28, 2024, 4:30 p.m. ET
Operator
Source Fool.com